Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD study of COR588 in healthy adults
NCT04920903Phase 1Completed
- Sponsor
- IRulya Therapeutics
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing COR588 with Placebo (2 arms). Primary endpoints: Incidence of treatment emergent adverse events at Day 19, Changes in chemistry lab measures at Day 19 and 2 more. Started Aug 2021; status: completed.
02
Drugs
COR588
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04920903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920903.